Acute-phase proteins and incidence of diabetes: a population-based cohort study

Iram Faqir Muhammad1 · Yan Borné1 · Bo Hedblad1 · Peter M. Nilsson1 · Margaretha Persson1 · Gunnar Engström1

Received: 3 June 2016 / Accepted: 18 August 2016 / Published online: 31 August 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Aims To examine the relationship between plasma levels of the acute-phase proteins ceruloplasmin, alpha-1-antitrypsin, orosomucoid, haptoglobin and C-reactive protein (CRP), and incidence of diabetes in the population-based Malmö Diet and Cancer Study—Cardiovascular Cohort (MDCS-CC).

Methods The study population consists of 4246 participants (aged 46–67 years, 60.8 % women) with no previous history of diabetes. Participants were followed, and incidence of diabetes was assessed by linkage with national registers and a clinical re-examination of the cohort. Cox proportional hazard regression analysis was used to compare incidence of diabetes in relation to sex-specific quartiles of the acute-phase proteins.

Results During a mean follow-up period of 15.6 ± 3.4 years, a total of 390 participants were diagnosed with diabetes. Orosomucoid, haptoglobin, and CRP showed a significant increased risk of diabetes after adjustment for potential confounders. However, further adjustments for fasting glucose at baseline resulted in significant association only for CRP. The multivariable-adjusted hazard ratios (HR: 4th vs. 1st quartile) were 1.18 (95 % CI: 0.83–1.67; \( p = 0.51 \)), 1.19 (CI: 0.85–1.62; \( p = 0.10 \)), and 1.40 (CI: 1.01–1.95; \( p = 0.046 \)) for orosomucoid, haptoglobin, and CRP respectively.

Conclusion The study demonstrated that there are associations between orosomucoid, haptoglobin and CRP and the risk of incidence of diabetes. However, after additional adjustment for fasting glucose levels at baseline, the association stayed significant only for CRP.

Keywords Acute-phase proteins · Diabetes · Incidence · Ceruloplasmin · Alpha-1-antitrypsin · Orosomucoid · Haptoglobin · CRP

Introduction

Diabetes, a major non-communicable disease, is one of the foremost public health and development challenges faced by the world today. The global prevalence of diabetes in 2014 was estimated to be 9 % among adults older than 18 years [1]. The World Health Organization projects that diabetes will be the seventh leading cause of death in the world by 2030 [2]. Age, obesity, physical inactivity, and family history of the disease are the major risk factors for type 2 diabetes [3].

Chronic low-grade inflammation has also been associated with the incidence of diabetes [4]. The relationship between development of diabetes and various inflammatory proteins has been explored in several studies previously; however, the results have been inconsistent [5–9]. The Women’s Health Study, a prospective study about the health of middle-aged women in the USA found that elevated level of C-reactive protein (CRP) and interleukin-6 (IL-6) predict development of type 2 diabetes in women [7]. Plasminogen activator inhibitor-1 (PAI-1) but not fibrinogen and CRP were found to predict type 2 diabetes in the Insulin Resistance Atherosclerosis Study, IRAS [5]. The results from the National Health and Nutrition
Examined diabetes in a population-based cohort. Mucoid, and haptoglobin at baseline and incidence of proteins (CRP, ceruloplasmin, alpha-1-antitrypsin, orosomucoid, and haptoglobin) was not associated with diabetes [8]. In another study, individuals at high risk of type 2 diabetes, using Hemoglobin A1c (HbA1c) criterion, showed an unfavorable inflammatory profile of five inflammatory markers (high-sensitivity hs-CRP, ESR, fibrinogen, white blood cell WBC count, and complement C3) as compared with control subjects [10].

Various acute-phase proteins have been associated with the development of diabetes and impaired glucose tolerance. Schmidt et al. studied the association of fibrinogen, orosomucoid, haptoglobin, and alpha-1-antitrypsin in new diabetes cases. The results showed strong association of orosomucoid with incidence of diabetes even when adjusted for different confounders [11]. Another study investigated the association of high levels of a score of five acute-phase proteins (fibrinogen, orosomucoid, alpha-1-antitrypsin, haptoglobin, and ceruloplasmin) with future weight gain [12]. Elevated levels of acute-phase proteins have been shown to associate with the prevalence of diabetes among overweight and obese men in the Malmö Preventive Project (MPP) [13].

The aim of this prospective study is to investigate the relationship between plasma levels of five acute-phase proteins (CRP, ceruloplasmin, alpha-1-antitrypsin, orosomucoid, and haptoglobin) at baseline and incidence of diabetes in a population-based cohort.

Materials and methods

Study population

The Malmö Diet and Cancer cohort (MDCS) included men born between 1923 and 1945 and women born between 1923 and 1950. Recruitment was carried out between March 1991 and September 1996. Out of 74,138 participants who were invited, a total of 30,447 participants (60% women) attended the baseline examinations [14]. A sub-cohort was obtained from the MDCS by randomly selecting participants between October 1991 and February 1994, with a primary aim of studying the epidemiology of carotid artery disease. The sub-cohort consisted of 6103 (2572 men and 3531 women) participants. Out of these, 5540 subjects agreed to give fasting blood samples for laboratory analysis [15]. Participants lacking data on acute-phase proteins (n = 858) ceruloplasmin, alpha-1-antitrypsin, orosomucoid, and haptoglobin were excluded from the analysis. For the acute-phase protein CRP, 113 participants had missing data. Participants with history of diabetes (n = 192) at baseline and those with fasting whole blood glucose of ≥6.1 mmol/L (n = 359) were also excluded from the study, hence leaving a final study population of 4246 (see “Appendix” for flowchart).

Baseline examinations

The MDCS baseline measurements comprised of a self-administered questionnaire, anthropometric measurements, and collection of blood samples [16]. Non-fasting blood samples were also drawn which were separated and stored in the biological bank at −80 °C. Information on family history of diabetes, current use of anti-hypertensive or anti-diabetic medications, smoking habits, leisure-time physical activity, educational level, and marital status were obtained from the questionnaire. Participants were classified into four categories regarding smoking habits: current smokers, occasional smokers, ex-smokers, and non-smokers. Low level of leisure-time physical activity was defined as the lowest quartile of a score revealed through 18 questions covering a range of activities in the four seasons [17]. The measurements of waist circumference (in cm) were carried out midway between the lowest rib margin and the iliac crest. Educational level was defined into three categories: school years <9, 9–12 and >12, respectively [14].

Information on fasting glucose was obtained through blood samples collected after an overnight fast. Participants with fasting whole blood glucose of ≥6.1 mmol/l, which corresponds to a fasting plasma glucose concentration of ≥7.0 mmol/l, as well as those who self-reported diabetes in the questionnaire or were taking anti-diabetic medication were classified as diabetics [18]. Blood glucose and HbA1c were analyzed from fasting blood samples by standardized procedures at the Department of Clinical Chemistry, Malmö University hospital. HbA1c was measured by ion exchange chromatography. The reference values in non-diabetic individuals were 3.9–5.3 % (19–34 mmol/mol). Insulin was measured by radioimmunoassay in mIU/l [15].

Measurements of fasting blood glucose and high-density lipoprotein (HDL) were performed in MDCS-CC on fresh blood samples according to standard procedures at the Department of Clinical Chemistry, University Hospital Malmö. Low-density lipoprotein cholesterol (LDL) concentration was calculated according to Friedewald’s formula.

High-sensitive CRP in plasma was analyzed using the Tina-quant® CRP latex assay (Roche Diagnostics, Basel, Switzerland). Plasma levels of ceruloplasmin, orosomucoid, haptoglobin, and alpha-1-antitrypsin were analyzed using Cobas c-systems (Roche Diagnostics GmbH, Germany). The reference values were 0.15–0.30 g/l for men and 0.16–0.45 g/l for women for ceruloplasmin [19]. For alpha-1-antitrypsin, the reference value was 0.9–2.0 g/l.
The reference value for orosomucoid was 0.5–1.2 g/l [19]. Finally, the reference value for haptoglobin was 0.3–2.0 g/l (www.roche.com) [19].

**Follow-up and endpoint definition**

All participants in the study were followed from the baseline examination until first diagnosis of diabetes, emigration from Sweden, death or December 31, 2009, whichever came first. New onset cases of diabetes in the cohort were gathered from different sources which have been described in detail previously [20]. To summarize, incident diabetes was identified by using the Malmö HbA1c register (MHR), the Swedish National Diabetes Register (NDR), the Swedish inpatient register, the Swedish outpatient register, the nationwide Swedish drug prescription register, and the regional Diabetes 2000 register of the Skåne region [20, 21]. The cases in the Diabetes 2000 register and NDR were based upon diagnosis by a physician according to recognized diagnostic criteria (fasting plasma glucose concentration of \( \geq 7.0 \text{ mmol/l} \), measured on two different occasions) [18].

**Statistical analysis**

CRP was log transformed due to the skewed distribution. The distribution for ceruloplasmin, haptoglobin, alpha-1-antitrypsin, and orosomucoid was approximately normal. Mean values (± standard deviations) and proportions were used to describe the baseline characteristics of the cohort for men and women. The acute-phase proteins were categorized into sex-specific quartiles, i.e., with equal proportion of men and women in each quartile. Linear regression was used to assess the association between acute-phase proteins and fasting blood glucose. Cox proportional hazard regression was used to compare the incidence of diabetes in different quartiles of individual proteins for the whole cohort. Hazard ratios (HRs) with 95% confidence interval (CI) were calculated. The significance level was defined as a \( p \) value of less than 0.05.

The HRs were adjusted for potential confounders in all the models. In the first model (Model 1), adjustments were made for age and sex. The second model (Model 2) was further adjusted for waist circumference, smoking habits (current and occasional smokers), physical activity, use of anti-hypertensive medication, systolic BP, HDL, and educational level. Finally, additional adjustments were done for baseline fasting blood glucose in Model 3 to demonstrate whether the associations were cross-sectional or prospective. Possible interactions between the plasma proteins and other risk factors for diabetes were investigated by introducing interaction terms in the multivariable model. The fit of the proportional hazards model was confirmed by plotting the incidence rate over time. The Kaplan–Meier curve was used to illustrate diabetes-free survival in relation to orosomucoid, haptoglobin, and CRP in sex-specific quartiles (Figs. 1, 2, 3).

Possible effect modification was assessed by modeling interaction terms between the acute-phase proteins and age, sex, and waist circumference, in the adjusted (Model 2) Cox’s proportional hazards models. All analyses were performed using IBM SPSS version 22 0 (SPSS Inc., Chicago, IL, USA).

Ethical approval was obtained from the Lund University Ethics Review Committee (LU51/90). All participants gave written informed consent.
Results

Baseline characteristics

The baseline characteristics of the study population in relation to sex have been presented in Table 1. Men and women were rather similar in terms of baseline characteristics. Men had slightly higher levels of glucose, waist circumference, and higher blood pressure and used more anti-hypertensive medications. Women had higher ceruloplasmin levels than men.

Correlations between acute-phase proteins and glucose

Ceruloplasmin, orosomucoid, haptoglobin, and CRP showed significant and positive correlations with fasting glucose, after adjustment for age and sex as shown in Table 2. This association remained statistically significant for orosomucoid and haptoglobin after further adjustment for the other covariates.

Incidence of diabetes in relation to acute-phase proteins

The mean follow-up period was 15.6 ± 3.4 years. A total of 390 participants (181 men and 209 women) were diagnosed with diabetes during the follow-up period. The incidence of diabetes was 7.19 per 1000 person-years in men and 5.09 per 1000 person-years in women.

Of the five acute-phase proteins, subjects in the fourth compared to the first quartile of orosomucoid, haptoglobin and CRP, respectively, had significantly higher risk of incidence of diabetes in the first model (Table 3). Figures 1, 2, and 3 illustrate the diabetes-free survival by quartiles of these acute-phase proteins. After adjustment for covariates in Model 2, this risk increase remained for orosomucoid (HR 1.46; 95 % CI 1.03–2.08), haptoglobin (HR 1.49; 95 % CI 1.08–2.05), and CRP (HR 1.44; 95 % CI 1.03–2.00). However, after also taking fasting blood glucose into account in Model 3, only CRP remained significant (HR 1.40; 95 % CI 1.01–1.95; Table 3).

Table 1 Baseline characteristics of the MDCS-CC among men and women (N = 4246)

| Baseline characteristics                          | Men       | Women     |
|--------------------------------------------------|-----------|-----------|
| N                                                | 1664      | 2582      |
| Incidence of diabetes n (n per 1000 p-y)          | 181 (7.19) | 209 (5.09) |
| Glucose (mmol/l)                                  | 5.01 ± 0.4 | 4.80 ± 0.4 |
| Age at baseline (years)                           | 57.63 ± 6.0 | 57.39 ± 5.9 |
| Ceruloplasmin (mg/l)                              | 0.46 ± 0.10 | 0.54 ± 0.12 |
| Alpha-1-antitrypsin (mg/l)                        | 1.19 ± 0.26 | 1.21 ± 0.26 |
| Orosomucoid (mg/l)                                | 0.71 ± 0.21 | 0.69 ± 0.20 |
| Haptoglobin (mg/l)                                | 1.30 ± 0.58 | 1.31 ± 0.51 |
| CRP (mg/l) (GM [5th–95th percentiles])            | 1.35 (0.30–8.30) | 1.29 (0.30–7.21) |
| Waist circumference (cm)                          | 92.15 ± 9.4 | 76.18 ± 9.5 |
| Low physical activity (%)                         | 20.9      | 22.4      |
| Current smoking status (%: current and occasional smokers) | 26.1    | 25.6      |
| Use of anti-hypertensive medication (%)           | 15.0      | 13.3      |
| Systolic BP (mmHg)                                | 142.4 ± 18.5 | 139.2 ± 18.9 |
| HDL (mmol/l)                                      | 1.23 ± 0.30 | 1.53 ± 0.35 |
| Low educational level (%)                         | 46.4      | 43.3      |

Data are mean ± SD unless otherwise indicated

p-y person year
Contrast to the findings of Schmidt et al. [11], who found an association of orosomucoid seen in our study is in levels of haptoglobin, orosomucoid, and CRP in a case-control study by McMillan, which showed increased association between orosomucoid and diabetes after adjustment for several potential confounders. However, after additional adjustment for fasting glucose, only CRP remained significantly associated with incident diabetes.

Previous studies have been inconsistent and different for different inflammatory markers. The present study revealed significant associations between the acute-phase proteins orosomucoid, haptoglobin, and CRP and increased incidence of diabetes when adjusted for several potential confounders. However, after additional adjustment for fasting glucose, only CRP remained significantly associated with incident diabetes.

There was a significant interaction between orosomucoid and waist ($p = 0.009$) when checked for effect modification, indicating a lower effect of orosomucoid in subjects with high waist circumference. No significant interaction was observed between the other acute-phase proteins, and age, sex, and waist in the adjusted model (Model 2).

### Discussion

Low-grade inflammation has been associated with the incidence of diabetes [4–10]. However, the results from previous studies have been inconsistent and different for different inflammatory markers. The present study revealed significant associations between the acute-phase proteins orosomucoid, haptoglobin, and CRP and increased incidence of diabetes when adjusted for several potential confounders. However, after additional adjustment for fasting glucose, only CRP remained significantly associated with incident diabetes.

The results are in accordance with a study from the Malmö Preventive Project, which reported nonsignificant relationships for ceruloplasmin, alpha-1-antitrypsin, haptoglobin and orosomucoid and incident diabetes after adjustments for fasting glucose and other risk factors [22]. The association of orosomucoid seen in our study is in contrast to the findings of Schmidt et al. [11], who found an association between orosomucoid and diabetes after adjustment for several potential confounders including glucose. Similar to our study, no relation was found for alpha-1-antitrypsin and haptoglobin with diabetes. However, we found cross-sectional significant correlations between glucose and haptoglobin and orosomucoid, respectively. This is in accordance with findings from a case-control study by McMillan, which showed increased levels of haptoglobin, orosomucoid, and CRP in association with diabetes and glucose intolerance [6]. Ceruloplasmin and alpha-1-antitrypsin were less markedly raised in participants with diabetes [6].

Many studies have shown association between CRP and type 2 diabetes [6]. A prospective analysis and meta-analysis conducted by Lee et al. [23] showed that there is evidence of association between CRP and incidence of diabetes. However, these results were explained by central adiposity and markers of liver dysfunction. The meta-analysis demonstrated an overall relationship between CRP and diabetes, but there was a substantial heterogeneity in the results between studies, which reduced the degree of evidence in the meta-analysis [23]. A retrospective study conducted in a Japanese health screening population, where obesity was not prevalent, showed that hs-CRP, but not WBC, was independently associated with incident diabetes [24]. In the present population-based study, the results were controlled for confounders including waist circumference and baseline glucose levels and showed significant association in results.

It is widely accepted that systemic low-grade inflammation is associated with diabetes. However, inflammation is a heterogeneous concept, and the association between different inflammatory markers is often moderate. Interleukin (IL)-6, IL-1beta, and tumor necrosis factor-alpha (TNF-$\alpha$) are important regulators of the hepatic production of acute-phase proteins [25, 26], but the regulation of the acute-phase protein production is very complex. Different cytokines operate in a network which results in additive, inhibitory, or synergistic regulatory effects of the production of different acute-phase proteins, depending on presence or absence of other cytokines and transcription factors, such as STAT3 or NF-kB [25]. Previous studies regarding the association between inflammation and incidence of diabetes have reported varying results for different inflammatory markers [5–9]. The varying relationships with incidence of diabetes could hypothetically be explained by differences with respect to the cytokines and transcription factors that regulate their production.

Dandona et al. [27] suggested two possible mechanisms involved in the pathogenesis of inflammation, and its link to obesity and diabetes. They proposed that firstly, chronic over-nutrition (causing obesity) can lead to a state of oxidative stress and hence inflammatory changes. Secondly, increased concentration of the pro-inflammatory cytokines such as TNF-$\alpha$ and IL-6 associated with obesity and diabetes might impair insulin action by suppressing insulin signal transduction [27]. The link between pro-inflammatory cytokines and insulin action was demonstrated by Hotamisligil et al., who showed increased expression of TNF-$\alpha$ in adipose tissue of obese rodents. A significantly increased peripheral uptake of glucose was observed in

### Table 2 Correlations between acute-phase proteins and glucose in non-diabetic individuals

| Protein          | Glucose (age, sex) | Glucose (risk factors) |
|------------------|--------------------|------------------------|
| Ceruloplasmin    | 0.035**            | 0.007                  |
| Alpha-1-antitrypsin | -0.004            | -0.004                 |
| Orosomucoid      | 0.152***           | 0.075***               |
| Haptoglobin      | 0.146***           | 0.095***               |
| LnCRP            | 0.105***           | -0.001                 |

Values are standardized beta coefficients, from a linear regression model with the acute-phase protein as the dependent variable

* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$

*a Risk factors: adjusted for age, sex, waist circumference, smoking, use of anti-hypertensive medication, systolic BP, HDL, low educational level, and low physical activity
response to insulin when TNF-α was neutralized in obese fa/fa rats [28]. It was further demonstrated that TNF-α induces insulin resistance through an inhibitory form of insulin receptor substrate 1 [29]. Dandona et al. [30] established the association of higher serum TNF-α concentrations with obesity and significant fall in the levels with weight loss. In addition, it has been shown that a single high-fat high-calorie meal results in inflammation with increased expression of NFkB and many pro-inflammatory cytokines, including TNF-α [31, 32] which suggests that dietary factors could be a common link between inflammation and diabetes.

Table 3  Incidence of diabetes in relation to sex-specific quartiles of five acute-phase proteins

| Protein                  | Q1     | Q2     | Q3     | Q4     | p for trend |
|--------------------------|--------|--------|--------|--------|-------------|
| Ceruloplasmin            |        |        |        |        |             |
| Mean ± SD                | 0.39 ± 0.050 | 0.47 ± 0.048 | 0.52 ± 0.046 | 0.65 ± 0.112 |             |
| Incidence of diabetes n (n/1000)\(^a\) | 74 (4.4) | 104 (6.3) | 111 (6.9) | 101 (6.0) |             |
| Model 1                  | 1      | 1.41 (1.05–1.90) | 1.52 (1.13–2.04) | 1.32 (0.98–1.79) | 0.074       |
| Model 2                  | 1      | 1.29 (0.95–1.77) | 1.33 (0.97–1.80) | 1.09 (0.79–1.49) | 0.739       |
| Model 3                  | 1      | 1.25 (0.92–1.71) | 1.36 (1.00–1.85) | 1.06 (0.78–1.46) | 0.748       |
| Alpha-1-antitrypsin      |        |        |        |        |             |
| Mean ± SD                | 0.88 ± 0.157 | 1.14 ± 0.049 | 1.27 ± 0.047 | 1.55 ± 0.197 |             |
| Incidence of diabetes n (n/1000)\(^a\) | 82 (5.3) | 119 (5.6) | 101 (6.7) | 88 (6.1) |             |
| Model 1                  | 1      | 1.10 (0.83–1.46) | 1.21 (0.90–1.62) | 1.19 (0.88–1.61) | 0.191       |
| Model 2                  | 1      | 1.20 (0.89–1.61) | 1.20 (0.88–1.64) | 1.18 (0.85–1.62) | 0.374       |
| Model 3                  | 1      | 1.27 (0.94–1.71) | 1.32 (0.97–1.81) | 1.27 (0.91–1.75) | 0.153       |
| Orosomucoid              |        |        |        |        |             |
| Mean ± SD                | 0.46 ± 0.059 | 0.60 ± 0.000 | 0.74 ± 0.050 | 1.10 ± 0.163 |             |
| Incidence of diabetes n (n/1000)\(^a\) | 53 (3.3) | 79 (5.5) | 152 (6.6) | 106 (8.4) |             |
| Model 1                  | 1      | 1.66 (1.17–2.35) | 1.99 (1.45–2.71) | 2.52 (1.81–3.50) | <0.001      |
| Model 2                  | 1      | 1.30 (0.91–1.87) | 1.25 (0.90–1.74) | 1.46 (1.03–2.08) | 0.058       |
| Model 3                  | 1      | 1.16 (0.81–1.67) | 1.06 (0.76–1.48) | 1.18 (0.83–1.67) | 0.510       |
| Haptoglobin              |        |        |        |        |             |
| Mean ± SD                | 0.68 ± 0.182 | 1.07 ± 0.099 | 1.44 ± 0.110 | 2.05 ± 0.410 |             |
| Incidence of diabetes n (n/1000)\(^a\) | 66 (4.1) | 79 (4.5) | 126 (7.0) | 119 (8.2) |             |
| Model 1                  | 1      | 1.07 (0.77–1.48) | 1.70 (1.26–2.29) | 2.06 (1.52–2.78) | <0.001      |
| Model 2                  | 1      | 1.00 (0.71–1.40) | 1.40 (1.03–1.92) | 1.49 (1.08–2.05) | 0.002       |
| Model 3                  | 1      | 0.91 (0.65–1.28) | 1.23 (0.90–1.67) | 1.19 (0.85–1.62) | 0.100       |
| CRP                      |        |        |        |        |             |
| Mean ± SD                | 0.41 ± 0.149 | 0.92 ± 0.170 | 1.81 ± 0.380 | 6.44 ± 6.714 |             |
| Incidence of diabetes n (n/1000)\(^a\) | 63 (3.7) | 72 (4.6) | 104 (6.4) | 143 (9.3) |             |
| Model 1                  | 1      | 1.24 (0.89–1.74) | 1.72 (1.26–2.36) | 2.59 (1.93–3.49) | <0.001      |
| Model 2                  | 1      | 1.10 (0.78–1.56) | 1.17 (0.84–1.64) | 1.44 (1.03–2.00) | 0.023       |
| Model 3                  | 1      | 1.24 (0.87–1.76) | 1.28 (0.92–1.79) | 1.40 (1.01–1.95) | 0.046       |

Model 1: Adjusted for age and sex
Model 2: Adjusted for age, sex, waist circumference, smoking, use of anti-hypertensive medication, systolic BP, HDL, low educational level, and low physical activity at baseline
Model 3: Adjusted for age, sex, waist circumference, smoking, use of anti-hypertensive medication, systolic BP, HDL, low educational level, low physical activity, and fasting glucose at baseline

\(^a\) Number of cases (incidence per 1000 person-years)
Many studies have shown associations between obesity, acute-phase proteins and diabetes [33, 34]. It can be argued that the link between inflammation and diabetes can be explained by the presence of obesity and adipose tissue which itself is a source of low-grade inflammation. However, this study has taken this fact into consideration, and the analysis has been adjusted for waist circumference. As the association is still significant, it can be speculated that there is a potential mechanism directly relating diabetes and inflammation. It should, however, be considered that previously it had been demonstrated that the association between CRP and diabetes is more likely to be non-casual, shown in the study by Brunner et al. [35]. Mendelian randomization was used in the study to demonstrate that the risk of developing diabetes was not associated with CRP levels in the European population. However, Brunner et al. [35] did not rule out the fact that acute-phase proteins early in the inflammatory process might be related to the development of diabetes.

Strengths and limitations

The data used for this study is derived from a large-scale population-based cohort with a participation rate of 41% [14]. The low participation rate stresses the importance to highlight the differences between the participants and non-participants in order to assess the external validity of the findings. Non-participants showed higher mortality than participants during and after the recruitment period, as well as during the follow-up. The participants in the MDCS were also compared to participants who took part in a mailed health survey (participation rate 75%) in the same population. The participants of the cohort study showed comparatively better health but were still representative of the population in terms of socioeconomic structure, smoking habits, and obesity [14].

One advantage of the prospective design is that it enables the collection of information on exposure variables before onset of disease, which decreases potential recall bias and risk of reverse causation. The large sample size and long follow-up period enable detection of a large number of endpoint cases. Moreover, information about endpoints for this study was retrieved from various national registers and several data sources as mentioned earlier and has high validity [36]. Although multiple sources were used to ensure detection of all endpoint cases, it should be taken into account that diabetes can go undetected for a long time, and participants who did not seek medical attention might have been missed.

Some methodological issues need to be considered. Since this is an observational study, confounding is a main concern. Adequate adjustment for probable confounders was carried out in the Cox regression models. Although the analysis was adjusted for several possible confounders, the possibility of residual confounding cannot be ruled out.

Another limitation of the study is that the plasma levels of the acute-phase proteins were measured only at the baseline. The levels may have changed over time before the incidence of the disease. Similarly, anthropometric measurements were also carried out during the baseline visits and might have changed over the study period. One more limitation of this study is regarding the information on the type of diabetes. As the study cohort consists of middle-aged subjects, it can be assumed that almost all cases developed type 2 diabetes, as type 1 diabetes most often manifests at a younger age, and therefore were excluded as prevalent diabetes at baseline [37]. Another point to consider is that the cohort included participants being residents of Malmö, Sweden, only. However, based on previous reports by McMillan [6], Schmidt et al. [11], and Lee [23], it seems likely that the results can be generalized to other populations as well.

Conclusion

In conclusion, this study demonstrated that there are associations between orosomucoid, haptoglobin, and CRP and the risk of incident diabetes. However, after additional adjustment for glucose, the association stayed significant for CRP. Further research in this regard is required to elucidate the underlying mechanism.

Acknowledgments The study was supported by the Swedish Research Council (Grant No. 2014-2265) and the Swedish Heart–Lung Foundation (Grant No. 2013-0249). We would like to acknowledge the information provided by the Nordic Diabetes Register, the Malmö HbA1c register, the Diabetes register 2000, and the registers provided by the Swedish Board of Health and Welfare.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical standard All procedures performed in this study involving human participants were in accordance with the ethical standards of the Lund University Ethics Review Committee and with the 1964 Declaration of Helsinki and its later amendments.

Human and animal rights disclosure The study was conducted in accordance with the principles of the Declaration of Helsinki of 1975, as revised in 2008.

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give

Springer
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Appendix

See Fig. 4.

Malmo Diet and Cancer Cohort (MDC):
Recruitment period: January 1991 to September 1996
n=30,447 (M=12,121 F=18,326)

MDC – Cardiovascular cohort (MDC-CC):
Recruitment period: October 1991 to February 1994
n=6103 (M=2572, F=3531)

Number of participants in MDC-CC who accepted invitations for fasting blood samples
n=5540

Number of participants with available data on acute phase proteins and with no history of diabetes and fasting whole blood glucose of <6.1 mmol/L at baseline
n=4246

Fig. 4 Flow chart

References

1. World Health Organization (2014) Global status report on non-communicable diseases. Available at: http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf?ua=1. Accessed 1 Jun 2016
2. Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3(11):e442
3. Fletcher B, Gulanick M, Lamendola C (2002) Risk factors for type 2 diabetes mellitus. J Cardiovasc Nurs 16(2):17–23
4. Pickup JC (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27(3):813–823
5. Festa A, D’Agostino R Jr, Tracy RP, Haffner SM, Insulin Resistance Atherosclerosis Study (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51(4):1131–1137
6. McMillan DE (1989) Increased levels of acute-phase serum proteins in diabetes. Metabolism 38(11):1042–1046
7. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286(3):327–334
8. Ford ES (2002) Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol 155(1):57–64
9. Ganrot PO, Gydel K, Ekelund H (1967) Serum concentration of alpha-2-macroglobulin, haptoglobin and alpha-1-antitrypsin in diabetes mellitus. Acta Endocrinol (Copenh) 55(3):537–544
10. Fiorentino TV, Hribal ML, Perticone M et al (2015) Unfavorable inflammatory profile in adults at risk of type 2 diabetes identified by hemoglobin A1c levels according to the American Diabetes Association criteria. Acta Diabetol 52(2):349–356
11. Schmidt MI, Duncan BB, Sharrett AR et al (1999) Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353(9165):1649–1652
12. Engstrom G, Hedblad B, Stavenov L, Lind P, Janzon L, Lindgarde F (2003) Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 52(8):2097–2101
13. Engstrom G, Stavenov L, Hedblad B et al (2003) Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. Diabetes 52(2):442–447
14. Manjer J, Carlsson S, Elmstahl S et al (2001) The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 10(6):489–499
15. Hedblad B, Nilsson P, Janzon L, Berglund G (2000) Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabetes Med 17(4):299–307
16. Berglund G, Elmstahl S, Janzon L, Larsson SA, The Malmo Diet and Cancer Study (1993) Design and feasibility. J Intern Med 233(1):45–51
17. Li C, Aronsson CA, Hedblad B, Gullberg B, Wirtfalt E, Berglund G (2009) Ability of physical activity measurements to assess health-related risks. Eur J Clin Nutr 63(12):1448–1451
18. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl 1):S5–S20
19. Konsensuswerte der Deutschen Gesellschaft für Laboratoriumsmedizin, der Deutschen Gesellschaft für Klinische Chemie und des Verbandes der Diagnostica-Industrie e.V. (VDGH) (1995) DG Klinische Chemie Mitteilungen 26:119–122
20. Enhorning S, Wang TJ, Nilsson PM et al (2010) Plasma copeptin and the risk of diabetes mellitus. Circulation 121(19):2102–2108
21. Melander O, Maisel AS, Almgren P et al (2012) Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA 308(14):1469–1475
22. Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F (2005) Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 54(2):570–575
23. Lee CC, Adler AI, Sandhu MS et al (2009) Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 52(6):1040–1047
24. Oda E (2015) High-sensitivity C-reactive protein, but not white blood cell count, independently predicted incident diabetes in a Japanese health screening population. Acta Diabetol 52(5):983–990
25. Bode JG, Albrecht U, Haussinger D, Heinrich PC, Schaper F (2012) Hepatic acute phase proteins—regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-kappaB-dependent signaling. Eur J Cell Biol 91(6–7):496–505
26. Moshage H (1997) Cytokines and the hepatic acute phase response. J Pathol 181(3):257–266
27. Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25(1):4–7
28. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259(5091):87–91
29. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271(5249):665–668
30. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T (1998) Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83(8):2907–2910
31. Ghanim H, Abuaysheh S, Sia CL et al (2009) Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 32(12):2281–2287
32. Fogarty CL, Nieminen JK, Peraneva L et al (2015) High-fat meals induce systemic cytokine release without evidence of endotoxemia-mediated cytokine production from circulating monocytes or myeloid dendritic cells. Acta Diabetol 52(2):315–322
33. Hotamisligil GS (1999) The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 245(6):621–625
34. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19(4):972–978
35. Brunner EJ, Kivimaki M, Witte DR et al (2008) Inflammation, insulin resistance, and diabetes—Mendelian randomization using CRP haplotypes points upstream. PLoS Med 5(8):e155
36. Ludvigsson JF, Andersson E, Ekblom A et al (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450
37. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ (2010) Epidemiology of type 1 diabetes. Endocrinol Metab Clin N Am 39(3):481–497